XML 72 R49.htm IDEA: XBRL DOCUMENT v3.8.0.1
Acquisitions, Divestitures, Research Collaborations and License Agreements - Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($)
$ in Millions
Jan. 21, 2015
Dec. 31, 2017
Dec. 31, 2016
Dec. 31, 2015
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]        
Goodwill   $ 18,284 $ 18,162 $ 17,723
Contingent consideration   $ 935 $ 891 $ 590
Cubist Pharmaceuticals Inc        
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]        
Cash and cash equivalents $ 733      
Accounts receivable 123      
Inventories 216      
Other current assets 55      
Property, plant and equipment 151      
Products and product rights (11 year weighted-average useful life) 6,923      
IPR&D 50      
Other noncurrent assets 184      
Current liabilities (233)      
Deferred income tax liabilities (2,519)      
Long-term debt (1,900)      
Other noncurrent liabilities (122)      
Total identifiable net assets 3,661      
Goodwill 4,670      
Consideration transferred $ 8,331      
Finite-lived intangible assets, useful life 11 years      
Cubist Pharmaceuticals Inc | Other current liabilities        
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]        
Contingent consideration $ 73      
Cubist Pharmaceuticals Inc | Other noncurrent liabilities        
Acquisitions Divestitures Research Collaborations And License Agreements Transactions [Line Items]        
Contingent consideration $ 50